MBX Biosciences, Inc. MBX Deferred Public Offering Costs Included In Accounts Payable And Accrued Expenses
Other financials
Where this comes from
Reported directly by MBX Biosciences, Inc. in its filing.
Tagged under the XBRL concept mbx:DeferredPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses.
The official record: MBX Biosciences, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about MBX Biosciences, Inc.'s deferred public offering costs included in accounts payable and accrued expenses.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is MBX Biosciences, Inc.'s deferred public offering costs included in accounts payable and accrued expenses?
- MBX Biosciences, Inc. (MBX) reported deferred public offering costs included in accounts payable and accrued expenses of $106K in Q1 2026.